Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: SeongJoon Cho/Bloomberg via Getty Images

Moderna announced Thursday it has requested an emergency use authorization from the U.S. Food and Drug Administration for its coronavirus vaccine for use in 12- to 17-year-olds.

Why it matters: The emergency use authorization would allow for the use of the vaccine in adolescents before Moderna receives full FDA approval, a key step in speeding up the country's race to herd immunity and reopening schools safely this fall.

  • The FDA has thus far only authorized Pfizer-BioNTech's COVID-19 vaccine for use in adolescents.
  • Moderna's vaccine was found to be safe and 100% effective at protecting against COVID-19 in a Phase 3 trial of more than 3,700 participants between the ages of 12 and 17.

What they're saying: "We have already filed for authorization with Health Canada and the European Medicines Agency and we will file with regulatory agencies around the world for this important younger age population. We remain committed to helping to end the COVID-19 pandemic," Moderna CEO Stéphane Bancel said in a statement.

Go deeper

The global vaccine supply is finally opening up

Illustration: Brendan Lynch/Axios

The global vaccine supply is finally opening up for countries that desperately need the ammo in the fight against the COVID-19 pandemic.

Driving the news: The Biden administration will buy 500 million doses of the Pfizer-BioNTech coronavirus vaccine to share with countries around the world, with the option to buy an additional 200 million.

Updated 13 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Emergency room visits of all kinds dropped amid the pandemic — NY smart-thermometer network could predict next COVID wave.
  2. Vaccines: FDA clears 10 million J&J vaccine doses from contaminated Baltimore plant — Moderna asks FDA to expand COVID-19 vaccine authorization to adolescents.
  3. Cities: Seattle becomes first major city to get 70% fully vaccinated — Schools nationwide prepare for packed kindergartens this fall.
  4. Work: Goldman Sachs requires U.S. employees to report vaccination status.
  5. Politics: U.S. to buy 500 million Pfizer doses to share with the world — State Department eases travel advisories for dozens of countries.
  6. World: Moscow orders new restrictions amid surge in COVID-19 cases — 12 Venezuela players, staff contract COVID-19 before Copa America opener — 2021 already has a higher global coronavirus death toll than 2020.
  7. 🎧 Podcast: Back to normal without herd immunity.
  8. Variant tracker: Where different strains are spreading.

U.S. to buy 500 million Pfizer doses to share with the world

Photo: Anna Moneymaker/Getty Images

The Biden administration will buy 500 million doses of the Pfizer-BioNTech coronavirus vaccine to share with countries around the world, with the option to buy an additional 200 million, two sources familiar with the deal tell Axios.

Why it matters: That's a big step toward making the U.S. a major global vaccine supplier and comes as Biden departs for his first foreign trip as president.